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Isobutylmethylxanthine Fails to Stimulate Chloride Secretion in Cystic
Fibrosis Airway Epithelia
Barbara Grubb, Eduardo Lazarowski, Michael Knowles, and Richard Boucher
Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
It has been proposed that a combination of an activated adenylyl cyclase and a high concentration of a
phosphodiesterase inhibitor (isobutylmethylxanthine [IBMX], 5 mM) stimulates CI- secretion mediated
by the heterologously expressed cystic fibrosis transmembrane regulator protein carrying the most com-
mon cystic fibrosis (CF) mutation (aF508). We tested whether CI- secretion could be stimulated by this
protocol in vitro and in vivo in CF airway epithelia expressing endogenous aF508 CFTR protein. In cul-
tured airway preparations, forskolin (a direct adenylyl cyclase activator) stimulated CI- secretion in
amiloride-pretreated normal (alsc = 7.1 ± 1.7 ~·cm-2) but not CF tissues (alsc = -0.2 ± 0.1
~·cm-2). Unexpectedly, IBMX partially inhibited the forskolin-induced CI- secretion in normal tis-
sues; IBMX addition had no effect on CF tissues. Direct measurements of cell cAMP concentrations re-
vealed that 0.1 mM IBMX and forskolin produced the maximum levels of cell cAMP levels attainable
with this drug combination, and 5 mM IBMX was without further effect. The combination of forskolin
(10-5 M) and isoproterenol, an adenylyl cyclase activator (10-5 M), produced approximately 3 times
higher levels of cAMP than forskolin/IBMX but also did not induce CI- secretion in CF tissues. Studies
of CI- secretion in vivo, assessed by the transepithelial electric potential difference (PD), showed that
isoproterenol (10-5 M) stimulated CI- secretion (aPD = -16.3 ± 4.3 mY; n = 4) in nasal epithelia of
normal subjects but not in CF patients homozygous for the aF508 mutation (aPD = -2.6 ± 1.9 mY;
n = 5). No additive effects of IBMX (5 mM) were observed in either group. We conclude that combina-
tions of adenylyl cyclase activators and IBMX are not effective in initiating CI- secretion in CF airway
epithelia.
Cystic fibrosis (CF) is expressed in the lung as a chronic bac-
terial infection of the airways that leads to diffuse bronchiec-
tasis (1). Although the detailed pathophysiology of CF lung
disease is not understood, it is likely that abnormal electro-
lyte transport is a primary contributor to airwaysdysfunction
in CF. A reduced capacity to secrete CI- ions toward the
airway lumen in response to agents that regulate cell cyclic
adenosine monophosphate (cAMP) levels, e.g., ,B-agonists
(2-4), and hyperabsorption of Na' ions from the airway lu-
men to the blood compartment (5-8) have both been re-
ported as electrolyte transport abnormalities in CF airways.
Pharmacologic therapies designed to modify abnormal
electrolyte transport in the CF lung may prove beneficial.
The Na' channel blocker, amiloride, provides partial pro-
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tection of the lung from disease-induced decline in airflow
obstruction (9). Further therapeutic benefit may be expected
from activating the defective CI- secretory path. Direct
pharmacologic studies of this problem have been made pos-
sible by the cloning of the CF gene (10). Using recombinant
DNA technology, the protein product of this gene, the "cystic
fibrosis transmembrane regulator" (CFTR), has been ex-
pressed in heterologous cell systems, e.g., Xenopus oocytes
(11). Initial reports suggest that CFTR is the cAMP-depen-
dent CI- channel itself (12, 13). In the recent studies of
Drumm and colleagues (11), data were obtained indicating
that frog oocytes expressing CFTR containing the common
phenylalanine deletion CF mutation aF508 could be stimu-
lated to generate a CI- current when exposed to a combi-
nation of a direct activator of adenylyl cyclase (forskolin) and
high concentrations (5 mM) of the phosphodiesterase inhibitor
isobutylmethylxanthine (IBMX). These researchers specu-
lated that partial CI- channel function of the mutated CFTR
(aF508) could be achieved by a high degree of cAMP-depen-
dent phosphorylation of the CFTR protein.
In the present study, we attempted to induce CI- secre-
tion in CF airway epithelia by raising intracellular cAMP to
high levels using combinations of adenylyl cyclase activators
and a high concentration ofIBMX. In vitro experiments em-
ploying cultured cell preparations and in vivo bioelectric
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measurements of the apical membrane CI- conductance of
airway epithelia were utilized.
Materials and Methods
Subjects
For the in vitro studies, nasal or bronchial specimens were
obtained from six CF patients during surgery for nasal ob-
struction or lung transplantation (3 males, 3 females; mean
age, 20.4 ± 3.4 yr). Five CF patients were genotyped, as fol-
lows: four were LlF50S/LlF50S; one LlF50S/unknown. Speci-
mens from normal subjects were obtained from nasal recon-
structive surgery (13 men, 4 women; mean age, 43.S ± 4.6
yr). All normal subjects had no family history of CF.
For the in vivo studies, five CF patients, homozygous for
the LlF50S mutation, were studied (3 men, 2 women; mean
age, 29.4 ± 1.6yr). Normal subjects for the in vivo electric
potential difference (PD) studies were age-matched for the
CF subjects (1 man; 3 women; mean age, 27.3 ± 1.3yr). All
were free of disease, were using no medications, and had no
family history of CF. All studies were approved by the
University of North Carolina Committee on the Rights of
Human Subjects.
Cell Culture
Cell culture techniques have been previously described (14).
In brief, cells were disaggregated from resected airway spec-
imens (4°C, 24 to 4S h; protease XIV; Sigma Chemical Co.,
St. Louis, MO), concentrated, and plated on collagen matrix
supports (CMS), 3.0 or 4.5 mm in diameter (two to six
preparations per patient) for bioelectric studies. Transwell-
Cols (1.2 em; Costar; Cambridge, MA) were employed in
studies of cAMP metabolism. Cells were maintained in F-12
media supplemented with insulin (10 j.tg/ml), endothelial cell
growth substance (7.5 j.tg/ml), transferrin (5 ILg/ml) , T3
(10-9 m), and hydrocortisone (5 X 10-9 M). After 5 days in
culture, the media was supplemented (1:1) with 3T3 cell con-
ditioned media (15). Cells plated on the CMS were moni-
tored daily for confluence and development of transepithelial
electric PD.
Measurement of cAMP Accumulation
cAMP accumulation was monitored essentially as described
previously (14, 16). Briefly,0.7 and 0.3 ml of Hepes-buffered
(20 mM, pH 7.5) Eagle's modified essential medium (MEM)
containing 2 to 3 j.tCi/ml of pH]adenine were added to the
serosal and mucosal side of the epithelial sheets, respec-
tively, and the cells were incubated for 3 h at 37°C. The
medium was aspirated, the cells were washed twice with
Hepes-MEM, and fresh aliquots, same volume as above, of
Hepes-MEM containing pertinent drugs were added. The
reactions were carried out at 37°C and were terminated at
the indicated times by aspiration of the medium followed by
the immediate bilateral addition of 5% trichloroacetic acid
containing 0.5 mM cAMP. PH]cAMP was separated from
PH]ATP by sequential passage of the trichloroacetic acid
extract over Dowex and alumina columns. Aliquots of the
cAMP fractions were assayed spectrophotometrically at 259
nm to correct for recovery of cAMP. Experiments were car-
ried out with triplicate samples that differed< 10% from the
mean. The results are expressed as the percent of conversion
of PH]ATP to PH]cAMP.
Bioelectric Characterization of Cl Transport
in Cultured Airway Epithelia
Cell preparations were mounted in Ussing chambers and
bathed in a Krebs bicarbonate Ringers solution that was
gassed (95% O2/5% CO2) and warmed (37°C). The prepa-
rations were voltage-clamped to record the short-circuit cur-
rent (Ise) , a measure of active ion transport rates. Trans-
epithelial voltage pulses (± 10 mV) were generated
intermittently (every 6 s) so that transepithelial resistance
could be calculated. Isc and the voltage pulses were
recorded on a strip chart recorder. After steady-state Isc
was achieved, drugs were added cumulatively. Amiloride
(10-4 M) was added to the apical bathing solution to con-
vert the tissues from the Nat-absorptive to the CI--
secretory mode (17). Forskolin, at a maximally effective
concentration (10-5 M) as determined in preliminary
studies, was added bilaterally and Isc was measured for 10
min. Preliminary studies in normal tissues showed that
IBMX was equally effective when applied to the apical or
basolateral surface, and the effects of exposure of each sur-
face to maximal IBMX concentration were not additive. Be-
cause of effectson ATP responses when applied to the apical
surface (see below), IBMX was usually applied to the
basolateral surface and Isc was monitored for an additional
10 min. In some experiments, a combination of isoprotere-
nol (10-5 M) and forskolin (10-5 M) was added after amilo-
ride with and without IBMX (0.1 mM) pretreatment. ATP
(10-4 M) was added to the apical surface at the end of each
protocol.
In Vivo Transepithelial Electric PD
The in vivo PD technique previously reported by Knowles
and co-workers (IS, 19) was employed. In brief, the trans-
epithelial PD was measured between a Ringer's-filled explor-
ing bridge (PE 50 tubing) positioned on the nasal mucosa
and a reference bridge (Ringer 4 % agar in a 21-gaugeneedle)
positioned underneath the skin of the forearm. The PD was
measured by a voltmeter (University of North Carolina
Department of Electronics) and recorded on the strip chart.
For delivery of drugs and solutions of different ionic compo-
sition, a second bridge (PE 50 tubing) positioned adjacent
to the exploring bridge was utilized to perfuse solutions at
the site of the PD measurement at the rate of 5 ml/min. The
typical protocol involved the following sequential measure-
ments: (1) steady-state PD « 5% change over 30 s) during
superfusion of either CI- -free (gluconate replacement)
Ringer's or low CI-, raised K+ solution containing amilo-
ride (10-4 M); (2) addition of the {1-agonist isoproterenol
(10-5 M) and amiloride on the mucosal surface for 3 min;
(3) superfusion of IBMX (5 mM), isoproterenol (10-5 M),
and amiloride for 5 min; (4) superfusion of ATP (10-4 M)
plus isoproterenol, IBMX, and amiloride onto the mucosal
surface for 2 min.
Solutions and Drugs
A Krebs Ringer's bicarbonate solution was utilized for in
vitro studies of cultured monolayers (20, 21). In some in vitro
studies, the apical solution of the culture was bathed by solu-
tions containing low CI- (3 mM CI-, CI- replaced by glu-
conate), raised K+ (100 mM, replacing Na"), and amilo-
ride (10-4 M). Similar solutions and CI--free only (gluconate
 
































replacement [22]) were utilized for the in vivo experiments,
except that 25 mM Hepes was utilized to buffer the pH of
the high K+, low CI- Ringer's solution because of the ina-
bility to keep the solution adequately gassed with 5 % CO2
throughout the perfusion tubing. Forskolin (Sigma) dis-
solved in a 10-2 M stock of ethanol vehicle, isoproterenol
(Sigma) dissolved in 10-2 M stock in appropriate vehicle,
and ATP (Boehringer Mannheim, Indianapolis, IN) dis-
solved in Ringer's as a 10-2 M stock were utilized. IBMX
(Sigma) was added to the Ussing chamber as a dry powder,
or as a suspension in Ringer's (50 mM stock), or after gener-
ation of a 200 mM stock solution (300 mM sucrose, pH 8.5
solution). No differences in bioelectric effects in normal tis-
sues were noted among the different delivery modes. For
cAMP studies, IBMX was dissolved in 0.1 N NaOH as a 50
mM stock. Solutions containing the desired final concentra-
tion of IBMX were adjusted to pH 7.4 with HCI before their














Under these conditions, forskolin induced a large increase
in Isc in normal tissues, whereas an inhibition of this cur-
rent was observed with addition of 5 mM IBMX (Figure
2B). There was no effect of forskolin or IBMX (5 mM) in
forskolin-pretreated tissues under these conditions in CF
tissues.
Because CF tissues failed to secrete CI- ions in re-
sponse to forskolin and IBMX, we tested the response of CF
preparations to a CI- secretagogue of a different class, ATP
(25). In preliminary studies, we noted that the presence of
5 mM IBMX bilaterally in the bathing solutions resulted in
a smaller response to mucosal ATP than typically observed
in normal or CF airway epithelia. In both normal (n = 9)
and CF (n = 5) tissues, the response to apical ATP was
blunted in the presence of apical IBMX (dIsc = 14.4 ± 2.1
jtA·cm-z, normal; dIsc 19.7 ± 8.9 jtA·cm-z, CF) as com
pared with basolateral IBMX (dIsc = 28.4 ± 5.9 j.tA·cm-Z,
normal; dIsc = 29.1 ± 8.6 j.tA·cm-2, CF; P < 0.05). Thus,
it appears that IBMX may be a relatively weak antagonist for
15 20
Time (min)
Figure 1. Cl secretory responses (Isc) of amiloride (10-4 M)-
pretreated cultured normal (A) and CF (B) airway epithelial prepa-
rations to cumulative addition of forskolin (10-5 M) and ffiMX
(5 mM).
Statistics
For the in vitro studies, the maximum change in Isc induced
by an agonist was compared with baseline. Significance of
changes was estimated by utilizing paired t tests for group
data (4 to 15 per group). To estimate the difference in re-
sponses to agonists between CF and normal preparations,
changes induced by agonists for the two groups were com-
pared by unpaired t tests. For the in vivo PD responses,
changes induced by agonists at different time points were
compared with basal PDs within a group by paired t tests and
the changes between the CF and normal groups compared
by unpaired t tests. Unless otherwise stated, all values are
mean ± SEM, with the number of tissues shown in paren-
theses.
Results
Figure 1 shows tracings of the responses of normal and CF
cell culture preparations, pretreated with amiloride to gener-
ate CI- secretion, to the sequential addition of forskolin
(10-5 M) and IBMX (5 mM). In response to forskolin, the
normal tissue shows an increase in the Isc, an index of CI-
secretion, followed by inhibition of Isc in response to addi-
tion of IBMX. The CF tissue exhibits a smaller residual Isc
after amiloride, consistent with the defective basal CI- con-
ductance that limits the capacity to generate a CI- secre-
tory current (2-4, 23). Neither forskolin alone nor forskolin
combined with IBMX induces a CI- secretory current in
the CF preparation. The mean data for a series of tissues ex-
posed to these maneuvers are shown in Figure 2A. Forskolin
routinely induces an increase in CI- secretion in normal
tissues followed by a modest inhibition of the forskolin-
stimulated CI- current with the subsequent addition of
IBMX. In contrast, CF tissues respond neither to forskolin
nor to the combination of forskolin and IBMX.
We used ion substitution maneuvers to increase the sensi-
tivity of the in vitro system to small effects of the IBMX on
the CI- secretory path (Figure 2B). In these studies, the
apical side was bathed with low CI-, raised K+ amiloride
(10-4 M)-containing solutions to generate a much larger
electrochemical driving force selectively favoring CI- se-
cretion than occurs after amiloride treatment alone (17, 24).
 
Grubb, Lazarowski, Knowles et al.: IBMX Fails to Stimulate Chloride Secretion in CF Airway Epithelia 457
A B 0
'<l' f--- Forskolin (0.01 mY) ------10 0
..... lD
•
eo 0 It:l,jI (")
co 0M
0.. 0
s: .-- ::1lC'":iN 0ta '<l' I <8 til 0
0 0 i'
.;: til .;: 0 M It:lI...-J ,













0 'Vi It:ltil I-< •
I 1I) .....
:>
0 l=:• M 0
I Forskolin IBMX I Forskolin IBMX u














Figure 2. Mean cr secretory response (dIsc) of amiloride (10-4
M)-pretreated cultured normal (hatched bars) and CF (solid bars)
airway epithelial preparations to cumulative addition of forskolin
(10-5 M) and IBMX (5 mM) in Ringer's solutions (A) or reduced
luminal cr solutions (B). Note change in scale of ordinate in
panels A and B.
the apical membrane P2 receptor previously reported on
these cells (25, 26). Importantly, the CF and normal cells
both respond to ATP with CI- secretion, indicating that the
lack of response to forskolin/IBMX in CF epithelia is not
due to unresponsive tissues.
Because IBMX failed to increase the rate of CI- secre-
tion of forskolin-treated normal and CF tissues (Figure 2),
we tested whether IBMX in the range of concentrations em-
ployed was capable of maximizing the cellular cAMP levels
in combination with forskolin. Results of the concentration-
effect relationship between added concentrations of IBMX-
and forskolin-stimulated cellular cAMP accumulation in epi-
thelial cultures are shown in Figure 3. Forskolin induced an
approximately 3-fold increase over basal cAMP levels. The
addition of IBMX further raises the intracellular cAMP
level, with a maximal effectiveconcentration of 0.1 mM. No
added effectsare seen with 5 mM as compared with 0.1 mM.
No differences were detected between CF and normal prepa-
rations.
We explored further the observation that IBMX inhibited
Isc after forskolin treatment in normal tissues. The inhibi-
tory effect of IBMX on Isc was similar when IBMX was de-
livered unilaterally on the basolateral or apical surface. The
absolute magnitude of the inhibition of Isc was directly
proportional (r = 0.79, P < 0.01; n = 11) to the magnitude
of the stimulation of Isc by forskolin. The dose dependence
of the inhibition was further investigated in forskolin-pre-
treated preparations that were sequentially exposedto 0.1 mM
followed by 5 mM IBMX in the apical or basolateral solu-
tion. The forskolin-induced current (~Isc = 12.5 ± 2.4
j.tA·cm-2) was not changed by the addition of 0.1 mM
IBMX (0.5 ± 0.2 j.tA·cm-2) , whereas the subsequent addi-
tion of 5 mM IBMX inhibited the current by 2.2 ± 0.5
j.tA·cm-2 (n = 5).
We performed two additional maneuvers in an attempt to
Figure 3. Effect of IBMX on forskolin-stimulated cAMP accumu-
lation in human nasal epithelium. Cells from normal subjects (solid
symbols) or CF patients (open symbols) were preincubated for 10
min with vehicle (basal) and with forskolin (10-5 M) alone or for-
skolin with the indicated concentration of IBMX. Squares denote
basal cAMP levels for normal subjects (solid square) and CF pa-
tients (open square). Circles denote values obtained during forsko-
lin treatment (see upper brackets) for normal subjects (solid circles)
and CF patients (open circles). The results were plotted as the per-
cent conversion of [3H]cAMP and are the mean of triplicate deter-
minations from four individuals.
stimulate CI- secretion in CF tissues in vitro. First, we
took advantage of synergism of forskolin and isoproterenol
to generate very high levels of intracellular cAMP (14). Al-
though the combination ofisoproterenol (10-5 M) and for-
skolin (10-5 M) was 3-fold more effective (36.7 ± 1.0%
conversion of ATP to cAMP) in raising cell cAMP levels
than forskolin (10-5 M) plus 0.1 mM IBMX (12.7 ± 3.4%
conversion of ATP to cAMP), this combination did not in-
duce CI- secretion in CF tissues (~Isc = 0.1 ± 0.5
j.tA·cm-2 , n = 5) and was no more effective in inducing
CI- secretion in normal tissues than forskolin alone (~Isc
= 11.2 ± 1.2 j.tA·cm-\ n = 3). Second, we attempted to
increase sensitivity by inhibiting possible dephosphorylation
of CFTR using okadaic acid, a phosphatase inhibitor (27).
Preliminary experiments suggested that 10-6 M okadaic acid
was the maximal concentration that could be delivered with-
out tissue damage. Pretreatment of normal tissues with oka-
daic acid (10-6 M) did not increase sensitivity to forskolin
(Msc = 10.2± 2.1 j.tA·cm-2 and 14.6 ± 1.78 j.tA·cm-2 with-
out and with okadaic acid, respectively; n = 3 each) nor did
it unmask responses to forskolin and IBMX in CF tissues
(~Isc = 0.1 ± 0.8 j.tA·cm-2 , n = 4). Similar findings were
observed with another phosphatase inhibitor, calyculinA (28).
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Figure 4. The change in nasal PD in vivo in normal subjects
(hatched bars) and CF patients (solid bars) in response to cumula-
tive addition of isoproterenol (10- 5 M) and IBMX (5 mM) during
superfusion with nominally CI- -free solutions containing amilo-
ride (10-4 M).
Finally, we tested whether IBMX could initiate CI-
secretion in vivo. The nasal lumen was superfused with CI--
free solutions containing amiloride to maximize sensitivity
of the technique to small changes in apical membrane CI-
conductance (22). Analysis of the steady-state responses re-
vealed that isoproterenol induced a sustained (3 min) in-
crease in PD in normal subjects and addition of IBMX had
no further effect (Figure 4). In contrast, in CF patients no
sustained responses were observed to isoproterenol or
IBMX during up to 6 min of superfusion. ATP was effective
in raising PD in both normal subjects(~PD = 11.3 ± 3.2 mY,
n = 3) and CF patients (~PD = 14.1 ± 2.1 mY, n = 3),
but the responses of both subject groups in the presence of
5 mM ffiMX were smaller than previously reported (29).
Discussion
These studies demonstrate that high concentrations of IBMX
(5 mM) combined with direct activation of adenylyl cyclase
(forskolin) in vitro or a receptor-mediated adenylyl cyclase
activator (isoproterenol) in vivo failed to stimulate CI-
secretion in CF airway epithelia. The large CI- secretory
responses of CF tissues to ATP, a CI- secretagogue of an-
other class (25, 26), indicate that the tissues were capable of
CI- secretion. The forskolin- or J3-agonist-stimulated CI-
secretory rates in normal tissues were not increased by
IBMX.
Because forskolin, J3-agonists, and IBMXmodulate CI-
secretory rates by a signal transduction system that involves
cAMP, the relationships between these agents and cell cAMP
levels were examined. Three key points emerged. First,
based on the observation that forskolin alone is maximally
effective in initiating CI- secretion (Figure 2), it appears
that a 3-fold increase in cell cAMP levels (Figure 3) is
sufficient to activate fully the cAMP-dependent pathway that
regulates CI- secretion in human airway epithelia (30).
This relationship is typical of other reports in which modest
increases in cell cAMP levels were sufficient to activate fully
cAMP-dependent effector pathways (31). Second, it appears
that 0.1 mM IBMX in forskolin-pretreated normal and CF
tissues generates the maximal concentration of cellular
cAMP possible by this combination of reagents in human air-
way epithelial cells (Figure 3). Thus, the failure of the CF
cells to respond to the combination of forskolin and IBMX
(up to 5 mM) does not reflect a failure of these agents to
achieve the maximal cellular cAMP concentrations possible
with this drug combination. Third, the drug combination of
isoproterenol and forskolin, operating synergistically on
adenylyl cyclase (14), generates approximately 3-fold higher
levels of cAMP than forskolin/IBMX but did not increase the
magnitude of CI- secretory rates in normal tissues or in-
duce CI- secretion in CF tissues. Thus, achieving cell
cAMP levels substantially higher than possible with the
combination of forskolin/IBMX does not activate CI-
secretion in CF airway epithelia.
High concentrations of IBMX (5 mM) had unexpected
effectson human airway epithelia. First, high concentrations
of IBMX may block the CI- secretory path. Inhibition of
Isc in normal but not CF tissues is consistent with an in-
hibitory action of IBMX on the CI- secretory path. Be-
cause there is no difference in cellular cAMP levels in re-
sponse to 0.1 and 5 mM ofIBMX, this inhibitory effectlikely
is a nonspecific effect of IBMX. Second, IBMX at high con-
centrations (5 mM) appears to have weak antagonist effects
on the purinergic receptor that transduces the ATP-induced
CI- current.
The reasons for the discrepancy between the data pre-
sented here and those of Drumm and colleagues (11) are not
clear but can be analyzed conceptually in several ways. The
first analysis focuses on the cellular metabolism of ~F508
CFTR and whether ~F508 CFTR maintains partial CI-
transport function. Recently, it has been suggested that the
mutated CFTR (~F508) is recognized as abnormal and
catabolized intracellularly before the insertion into the
plasma membrane site required for CI- transport (32). It is
conceivable that the overexpression of ~F508 CFTR and/or
perhaps inefficient intracellular catabolism of a foreign pro-
tein in frog oocytes permits partially functional (33) ~F508
CFTR protein to be inserted in the oocyte membrane, where
it is available for induction of cAMP-dependent CI- trans-
port. The failure offorskolin and IBMX to stimulate endoge-
nous ~F508-mediated transport in airway epithelia could
reflect the relatively low level of endogenous production of
CFTR by airway epithelia (34) and/or efficient intracellular
catabolism of ~F508 CFTR in airway epithelia, resulting in
little or no ~F508 CFTR in the plasma membrane for cAMP-
dependent CI- transport. A second possible explanation for
the difference between our results and those of Drumm and
colleagues (11) relates to the temperature at which the cells
were cultured. It has been shown that 3T3 fibroblasts trans-
fected with ~F508 CFTR and maintained at 37°C failed to
express a cAMP-mediated CI- conductance, whereas when
these cells were maintained at 26°C, cAMP agonists induced
a CI- conductance in them (35). Our airway epithelia were
cultured at 37°C, whereas frog oocytes, which were em-
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ployed in the study by Drumm and colleagues (11), are usu-
ally maintained at 26°C. The third possible difference be-
tween our study and that of Drumm's group (11) focuses on
the level of phosphorylation of CFTR and its activity. It is
conceivable that the degree of phosphorylation of CFTR is
critical for activation of CI- transport (11), and that the
AF508 CFTR endogenously expressed in airway epithelia
cannot be phosphorylated to the same extent as the AF508
CFTR that is expressed in the frog oocyte system. The obser-
vation that CI- secretion in normal cells is maximally stim-
ulated at less than maximal levels of cell cAMP indicates that
the cellular phosphorylating activity (cAMP-dependent pro-
tein kinase) required for activation of CI- secretion in air-
wayepithelia is fully maximized by forskolin alone. No com-
parative cellular cAMP data are available in the oocyte
system. It is also conceivable that the phosphorylation of
AF508 CFTR is lower in airway epithelia than in the oocyte
because of relatively greater dephosphorylation (phospha-
tase) activity in airway epithelia. Although it is not yet
known which cellular phosphatases are active on CFTR,
treatment of airway epithelia with known permanent phos-
phatase inhibitors did not unmask effectsof cAMP elevation
on CI- secretion in CF airway epithelia.
In summary, the combination of activators of adenylyl cy-
clase and high concentrations of the phosphodiesterase in-
hibitor, IBMX, did not initiate CI- secretion in CF airway
epithelia in vitro or in vivo. Thus, treatment of CF patients
with high concentrations of methylxanthines, including the-
ophylline, with the goal of inducing CI- secretion does not
appear warranted. Indeed, IBMX at very high concentra-
tions may have nonspecific effects, e.g., a block of CI- con-
ductance and inhibition of P, receptors. In addition, it has
been shown that agents that raise cell cAMP in CF airways
may further increase the abnormally high basal rate of Na'
transport (6). Thus, the development of CI- secretagogues
in CF airway epithelia that focus on elevating the levels of
cell cAMP concentrations may be unproductive, and strate-
gies focusing on alternative pathways, such as purinoceptors,
may be preferable.
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